Item no. |
HY-109171-50mg |
Manufacturer |
MedChem Express
|
CASRN |
929046-33-3 |
Amount |
50 mg |
Quantity options |
100 mg
10 mM/1 mL
10 mg
1 mg
25 mg
50 mg
5 mg
|
Category |
|
Type |
Molecules |
Specific against |
other |
Purity |
99.82 |
Formula |
C33H35F7N4O3 |
Citations |
[1]Alvaro, Giuseppe; Andreotti, Daniele; Belvedere, Sandro; Di Fabio, Romano; Falchi, Alessandro; Giovannini, Riccardo.Pyridine derivatives as NK receptor inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of psychotic disorders.CN101305011B [2]Simon JA, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar 1;30(3):239-246. [3]Steve Pawsey, et al. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234. |
Smiles |
CC(C)(C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C(N(C2=CN=C(N3[C@@H](CN4[C@@](COCC4)([H])C3)CO)C=C2C5=C(C=C(C=C5)F)C)C)=O |
ECLASS 10.1 |
32169090 |
ECLASS 11.0 |
32169090 |
UNSPSC |
12000000 |
Alias |
NT-814, BAY3427080 |
Shipping condition |
Room temperature |
Available |
|
Manufacturer - Type |
Reference compound |
Manufacturer - Applications |
Neuroscience-Neuromodulation |
Manufacturer - Targets |
Neurokinin Receptor |
Shipping Temperature |
Room Temperature |
Storage Conditions |
-20°C, 3 years; 4°C, 2 years (Powder) |
Molecular Weight |
668.64 |
Product Description |
Elizanetant (NT-814) is an orally active, selective NK-1, 3 receptor antagonist. Elizanetant can improve vascular dilation and schizophrenia, and reduce levels of estradiol and progesterone[1][2][3]. |
Manufacturer - Research Area |
Neurological Disease; Cardiovascular Disease |
Solubility |
DMSO : 100 mg/mL (ultrasonic) |
Manufacturer - Pathway |
GPCR/G Protein; Neuronal Signaling |
Clinical information |
Phase 3 |